Skip to main content

Omega Funds — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

82
Companies
$7.9B
Total invested
$96.5M
Avg. check
19
Industries
Biotechnology 19Health Care 16Medical 12Medical Device 8Biopharma 6Life Science 5+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 82
Anaconda BioMed
September 2026

Anaconda Biomed is a medical device start-up that develops the next generation of catheters to perform efficient mechanical thrombectomies.

Health Care · Barcelona$56.0M Series C
Beta Bionics
September 2026

Beta Bionics is a biotechnology company that provides software to reduce the burden of diabetes care.

Biotechnology · Irvine$172.5M Post-IPO Equity
Vaderis Therapeutics
August 2026

Vaderis Therapeutics is a clinical-stage biotechnology company developing targeted therapies for rare vascular diseases.

Biotechnology · Basel$152.0M Series B
Editas Medicine
May 2026

Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.

Biotechnology · Cambridge$125.0M Post-IPO Equity
Sana Biotechnology
May 2026

Sana Biotechnology is a developer of engineered cells intended to be used as medicine for patients.

Biotechnology · Seattle$69.0M Post-IPO Equity
Spruce Biosciences
April 2026

Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.

Biopharma · South San Francisco$60.0M Post-IPO Equity
Trevi Therapeutics
April 2026

Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.

Biotechnology · Sandy Hook$173.0M Post-IPO Equity
Caldera Therapeutics
January 2026

Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).

Biopharma · Cambridge$37.5M Series A
Spiro Medical
January 2026

Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment.

Biotechnology · Menlo Park$67.0M Series A
FoRx Therapeutics
December 2025

FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways.

Biotechnology · Basel$50.0M Series A
Kestra Medical Technologies, Inc.
December 2025

Kestra Medical Technologies offers wearable medical devices which collects, store, and communicate patients vital performance data.

Health Care · Kirkland$138.0M Post-IPO Equity
Protego Biopharma
December 2025

Protego Biopharma is a biotechnology company that develops therapeutics that aim to correct diseases caused by protein misfolding.

Biopharma · San Diego$130.0M Series B
NRG Therapeutics
September 2025

NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function.

Biopharma · Cambridge$67.5M Series B
ARTBIO
July 2025

ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.

Biotechnology · Cambridge$132.0M Series B
Antares Therapeutics
May 2025

Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.

Biopharma · Boston$177.0M Series A
Ousia Pharma
May 2025

Ousia Pharma focuses on the design and development of pharmacotherapies to improve the health and lives of people living with obesity.

Biotechnology · CopenhagenSeed
Hydrocision
April 2025

HydroCision develops, manufactures, and markets fluid jet-based surgical tools for minimally invasive spine surgery requirements.

Health Care · North Billerica$2.5M Venture - Series Unknown
Callio Therapeutics
March 2025

Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).

Biotechnology · Seattle$187.0M Series A
Alleviant Medical
January 2025

Alleviant Medical develops transcatheter technology designed to lift the clinical and economic burden of heart failure.

Biotechnology · Austin$90.0M Venture - Series Unknown
XII Medical
August 2024

XII Medical provides minimally invasive technology for obstructive sleep apnea.

Health Care · Union City$45.0M Series B
CatalYm
July 2024

CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.

Biotechnology · Planegg$150.0M Series D
Vanqua Bio
July 2024

Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases.

Biotechnology · Chicago$45.0M Venture - Series Unknown
BBOT
May 2024

BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3K malignancies.

Biopharma · Palo Alto$200.0M Venture - Series Unknown
Endeavor BioMedicines
April 2024

Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.

Biotechnology · Solana Beach$132.5M Series C

Where Omega Funds invests

Biotechnology19
Health Care16
Medical12
Medical Device8
Biopharma6
Life Science5

About Omega Funds's portfolio

How many companies has Omega Funds invested in?▸

Omega Funds has invested in 82 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Omega Funds invest in?▸

Omega Funds's top investment sectors include Biotechnology, Health Care, Medical, Medical Device, Biopharma. The firm invests across 19 different industry categories.

What is Omega Funds's largest investment?▸

Among tracked funding rounds, BBOT received $200.0M in a Venture - Series Unknown round. Omega Funds's total known invested capital is $7.9B.

What is the average investment size for Omega Funds?▸

Omega Funds's average investment size is $96.5M across its portfolio of 82 companies.

What are Omega Funds's most recent investments?▸

Recent Omega Funds portfolio additions include Anaconda BioMed, Beta Bionics, Vaderis Therapeutics, Editas Medicine, Sana Biotechnology. These companies were founded in 2020 or later.

Reach the founders behind these 82 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →